
        <!DOCTYPE html>
        <html>
        <head>
            <title>Celldex Therapeutics Inc. (CLDX) - Articles</title>
            <meta name="viewport" content="width=device-width, initial-scale=1.0">
            <style>
                :root {
                    --primary-color: #000000;
                    --secondary-color: #666666;
                    --accent-color: #d5001c;
                    --text-color: #2c3e50;
                    --border-color: #e0e0e0;
                    --hover-color: #f8f9fa;
                }
                
                body { 
                    font-family: "Porsche Next", "Segoe UI", Arial, sans-serif;
                    margin: 0;
                    padding: 0;
                    color: var(--text-color);
                    background-color: #f5f6fa;
                    line-height: 1.6;
                }
                
                .header {
                    background: linear-gradient(135deg, #000 0%, #1a1a1a 100%);
                    padding: 25px 0;
                    box-shadow: 0 2px 10px rgba(0,0,0,0.2);
                    position: sticky;
                    top: 0;
                    z-index: 1000;
                    backdrop-filter: blur(10px);
                }
                
                .header::before {
                    content: '';
                    position: absolute;
                    top: 0;
                    left: 0;
                    right: 0;
                    bottom: 0;
                    background: radial-gradient(circle at 30% 50%, rgba(255,255,255,0.08) 0%, rgba(255,255,255,0) 70%);
                    pointer-events: none;
                }
                
                .header-content {
                    max-width: 1400px;
                    margin: 0 auto;
                    padding: 0 30px;
                    display: flex;
                    justify-content: space-between;
                    align-items: center;
                }
                
                .header-title {
                    font-size: 28px;
                    font-weight: 300;
                    color: #fff;
                    margin: 0;
                    letter-spacing: 1px;
                }
                
                .back-btn {
                    background: rgba(255,255,255,0.1);
                    border: 1px solid rgba(255,255,255,0.2);
                    padding: 10px 20px;
                    color: #fff;
                    text-decoration: none;
                    font-size: 14px;
                    border-radius: 4px;
                    transition: all 0.3s ease;
                    backdrop-filter: blur(5px);
                }
                
                .back-btn:hover {
                    background: rgba(255,255,255,0.2);
                    transform: translateY(-2px);
                }
                
                .container {
                    max-width: 1400px;
                    margin: 40px auto;
                    padding: 0 30px;
                }
                
                .stats-container {
                    display: grid;
                    grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
                    gap: 20px;
                    margin-bottom: 40px;
                }
                
                .stat-card {
                    background: #fff;
                    border-radius: 12px;
                    padding: 25px;
                    text-align: center;
                    box-shadow: 0 4px 20px rgba(0,0,0,0.08);
                    transition: transform 0.3s ease;
                }
                
                .stat-card:hover {
                    transform: translateY(-5px);
                }
                
                .stat-value {
                    font-size: 32px;
                    font-weight: 300;
                    color: var(--primary-color);
                    margin-bottom: 10px;
                }
                
                .stat-label {
                    font-size: 14px;
                    color: var(--secondary-color);
                    text-transform: uppercase;
                    letter-spacing: 1px;
                }
                
                .articles-grid {
                    display: grid;
                    grid-template-columns: repeat(auto-fill, minmax(400px, 1fr));
                    gap: 30px;
                    margin-top: 40px;
                }
                
                .article-card {
                    background: #fff;
                    border-radius: 12px;
                    overflow: hidden;
                    box-shadow: 0 4px 20px rgba(0,0,0,0.08);
                    transition: all 0.3s ease;
                }
                
                .article-card:hover {
                    transform: translateY(-5px);
                }
                
                .article-content {
                    padding: 25px;
                }
                
                .article-title {
                    font-size: 18px;
                    font-weight: 400;
                    margin: 0 0 15px;
                    line-height: 1.4;
                }
                
                .article-title a {
                    color: var(--primary-color);
                    text-decoration: none;
                    transition: color 0.2s ease;
                }
                
                .article-title a:hover {
                    color: var(--accent-color);
                }
                
                .article-meta {
                    display: flex;
                    align-items: center;
                    gap: 20px;
                    margin-bottom: 15px;
                    font-size: 14px;
                    color: var(--secondary-color);
                }
                
                .article-sentiment {
                    padding: 4px 12px;
                    border-radius: 20px;
                    font-weight: 500;
                    font-size: 14px;
                }
                
                .article-sentiment.positive {
                    background: rgba(40,167,69,0.1);
                    color: #28a745;
                }
                
                .article-sentiment.negative {
                    background: rgba(220,53,69,0.1);
                    color: #dc3545;
                }
                
                .article-sentiment.neutral {
                    background: rgba(108,117,125,0.1);
                    color: #6c757d;
                }
                
                .article-summary {
                    font-size: 14px;
                    color: var(--text-color);
                    line-height: 1.6;
                    margin-top: 15px;
                    opacity: 0.8;
                }
                
                @media (max-width: 768px) {
                    .header-content {
                        padding: 0 20px;
                    }
                    
                    .header-title {
                        font-size: 20px;
                    }
                    
                    .container {
                        padding: 0 20px;
                        margin: 20px auto;
                    }
                    
                    .articles-grid {
                        grid-template-columns: 1fr;
                        gap: 20px;
                    }
                    
                    .stat-card {
                        padding: 20px;
                    }
                    
                    .stat-value {
                        font-size: 28px;
                    }
                }
            </style>
        </head>
        <body>
            <div class="header">
                <div class="header-content">
                    <h1 class="header-title">Celldex Therapeutics Inc. (CLDX)</h1>
                    <a href="index.html" class="back-btn">← Back to Dashboard</a>
                </div>
            </div>
            
            <div class="container">
                <div class="stats-container">
                    <div class="stat-card">
                        <div class="stat-value">9</div>
                        <div class="stat-label">Total Articles</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">4</div>
                        <div class="stat-label">Positive Articles</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">4</div>
                        <div class="stat-label">Negative Articles</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">-0.12</div>
                        <div class="stat-label">Average Sentiment</div>
                    </div>
                </div>
                
                <div class="articles-grid">
        
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=9d461e0b4d97e55d511f3c6e3d7bd785423f7c2d101af7c9409b9c8f2264c2be" target="_blank" rel="noopener noreferrer">Chronic Inducible Urticaria (CIndU) Market Research Report 2025-2035 | Competitive Analysis of AstraZeneca, Celldex Therapeutics, J&J, Merck, Novartis, Pfizer, Regeneron Pharma, Sanofi, Sun Pharma</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-27</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.53
                                </span>
                            </div>
                            <div class="article-summary">The global chronic inducible urticaria (CIndU) market is experiencing significant transformation due to rising prevalence, advancements in diagnostics, and targeted immunotherapies. Affecting 0.1% to ...</div>
                        </div>
                    </div>
            
                    <div class="article-card negative">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=1bc761c33738cf7ac925ce50ddc42a208b42e00e3a504d471b5ea1e153bbe1be" target="_blank" rel="noopener noreferrer">FDA cancels adcomm on Biohaven drug; Catalent lays off staff</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-22</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment negative">
                                    -0.96
                                </span>
                            </div>
                            <div class="article-summary">Analysts found the agency's decision to cancel the meeting encouraging. Elsewhere, the Novo Holdings-owned CDMO cut about 350 staff in Maryland....</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=ae22a8255708736b8f8e9779a043a16046cdbc111c7c77bda324be25efc77d61" target="_blank" rel="noopener noreferrer">Celldex: Despite Dropping Eosinophilic Esophagitis Program, Barzolvolimab On Track</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-21</span>
                                <span>SeekingAlpha</span>
                                <span class="article-sentiment positive">
                                    0.36
                                </span>
                            </div>
                            <div class="article-summary">Celldex Therapeutics, Inc.'s barzolvolimab has promise in urticaria treatment despite an eosinophilic esophagitis trial setback. Click for my updated look at CLDX....</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=67d99df4198c9bb4c1ac7a8d905ff5fc061e3dcaa67bc1f651b5d0de88de4e3a" target="_blank" rel="noopener noreferrer">LifeSci Capital Maintains a Buy on Celldex Therapeutics (CLDX), Keeps the PT</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-20</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.52
                                </span>
                            </div>
                            <div class="article-summary">Celldex Therapeutics, Inc. (NASDAQ:CLDX) is one of the Best Small-Cap Growth Stocks to Buy Right Now. On August 12, Sam Slutsky from LifeSci Capital maintained a Buy rating on Celldex Therapeutics, In...</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=85b09b262ad1e16d27222e1e9dc10401566bad6c1661e0e16f89498781204d8b" target="_blank" rel="noopener noreferrer">Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE)</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-19</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">Study met primary endpoint demonstrating barzolvolimab’s ability to potently deplete mast cells in the gastrointestinal tractProfound mast cell depletion did not result in improved clinical outcomes p...</div>
                        </div>
                    </div>
            
                    <div class="article-card negative">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=ddcd4d1c275b315f64f163a1f9e378ba3a542e963e8b36e9f175223abf2ea913" target="_blank" rel="noopener noreferrer">Celldex Therapeutics Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-10</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment negative">
                                    -0.92
                                </span>
                            </div>
                            <div class="article-summary">Celldex Therapeutics ( NASDAQ:CLDX ) Second Quarter 2025 Results Key Financial Results Net loss: US$56.6m (loss widened......</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=2ff5f062219af5462b5e7a4876a260bda9c710d8bffe8d185080600ce29bd286" target="_blank" rel="noopener noreferrer">Celldex Reports Second Quarter 2025 Financial Results and Provides Corporate Update</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-07</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.55
                                </span>
                            </div>
                            <div class="article-summary">Strong execution and continued progress across pipeline Unprecedented data delivered from Phase 2 CSU study demonstrating profound, sustained complete response and improved quality of life 7 months af...</div>
                        </div>
                    </div>
            
                    <div class="article-card negative">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=9fa1fa2d4bef1d3e90c2937604c3619e721a9c1b405d988df252babee50f1d99" target="_blank" rel="noopener noreferrer">Celldex: Q2 Earnings Snapshot</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-07</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment negative">
                                    -0.78
                                </span>
                            </div>
                            <div class="article-summary">HAMPTON, N.J. (AP) — Celldex Therapeutics Inc. CLDX) on Thursday reported a loss of $56.6 million in its second quarter. The Hampton, New Jersey-based company said it had a loss of 85 cents per share....</div>
                        </div>
                    </div>
            
                    <div class="article-card negative">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=fe2f6c57968aa24c327a4243c2493e84a66d4794c9478ed34312a7e6f710229a" target="_blank" rel="noopener noreferrer">Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-08-07</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment negative">
                                    -0.39
                                </span>
                            </div>
                            <div class="article-summary">Celldex (CLDX) delivered earnings and revenue surprises of +1.16% and -56.18%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?...</div>
                        </div>
                    </div>
            
                </div>
            </div>
        </body>
        </html>
        